Dimeric polypeptide radiopharmaceuticals targeting integrin α6 and preparation method thereof

The present invention discloses a dimeric polypeptide radiopharmaceutical targeting integrin α6 and a preparation method thereof. The radiopharmaceutical comprises a cKiE dimer polypeptide and a radionuclide, wherein the radionuclide is labeled with the cKiE dimer polypeptide through a bifunctional chelating agent; the cKiE dimer polypeptide is dimerized by two cKiE polypeptide monomers connected by a linker; the cKiE polypeptide monomer is a cyclic polypeptide, and the cyclic polypeptide is composed of an amino acid molecular chain with the sequence of Lys-Arg-Trp-Tyr-Asp-Glu-Asn-Ala-Glu connected head to tail; the linker is an amino acid molecular chain in which 3-5 inert amino acid molecules are sequentially connected or a polyethylene glycol with a polymerization degree of 3-12, and the inert amino acid is glycine or serine. The cyclic polypeptide sequence of the radiopharmaceutical of the invention will not be recognized by proteases in vivo, and can effectively improve the in vivo metabolic stability, thereby improving the uptake of tumor tissue.


Dimeric polypeptide radiopharmaceuticals targeting integrin α6 and preparation method thereof - cover page
Category
Other
Document type
Other
Language
Chinese
Pages
21
File format
PDF
File size
1.2 MB
Published
16 November, 2023
Updated
16 November, 2023
MD5 checksum
71DCFB6EBC26220F4FABD68639E541B1

About this manual

This patent application describes a dimeric polypeptide radiopharmaceutical targeting integrin α6. It comprises a cKiE dimeric polypeptide and a radionuclide, with the radionuclide attached through a bifunctional chelator; the cKiE monomer is a cyclic peptide with the amino acid sequence Lys-Arg-Trp-Tyr-Asp-Glu-Asn-Ala-Glu.

The application also describes preparation methods using HYNIC or DOTA chelators and radionuclides such as 99mTc or 68Ga, and states that the radiopharmaceutical is used to prepare an imaging diagnostic agent for patients with integrin α6-positive tumors. This manual is written in Chinese.

What's inside

  • Technical field
  • Background art
  • Summary of invention
  • Claims
  • Application

Specifications

cKiE monomer sequenceLys-Arg-Trp-Tyr-Asp-Glu-Asn-Ala-Glu
Linker3-5 inert amino acids or polyethylene glycol with degree of polymerization 3-12
Inert amino acidsGlycine or serine
Radionuclides99mTc, 68Ga, 64Cu, 111In, 90Y, or 177Lu
Bifunctional chelatorsHYNIC, DOTA, NOTA, or DTPA
Linker examplesGGG, SSS, GSS, GGS, GSG, GGGG, or GGGGG
Polyethylene glycol linkerDegree of polymerization 4
Pharmacokinetic modifierPolyethylene glycol with degree of polymerization 4 or 8-aminooctanoic acid
Physical formColorless transparent liquid injection
Intended useImaging diagnostic agent for patients with integrin α6-positive tumors

Frequently asked questions

What is the amino acid sequence of the cKiE monomer?

The cyclic peptide monomer has the sequence Lys-Arg-Trp-Tyr-Asp-Glu-Asn-Ala-Glu.

Which radionuclides can be used to label the radiopharmaceutical?

The radionuclide can be 99mTc, 68Ga, 64Cu, 111In, 90Y, or 177Lu.

What is the intended diagnostic use?

It is used to prepare an imaging diagnostic agent for patients with integrin α6-positive tumors.

What physical form is described for the radiopharmaceutical?

The polypeptide radiopharmaceutical is described as a colorless transparent liquid injection.

Download PDF (1.2 MB)

Also Manuals